NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

NanoViricides, Inc., a clinical-stage company, emphasizes the development of its antiviral drug NV-387 to combat escalating viral threats such as measles and MPox. Amidst rising measles cases in Europe and the US, NV-387 emerges as a potential solution due to the increasing vaccine failure rates and falling vaccination coverage. Notably, NV-387 is the only drug candidate available to counter the measles virus.

The company is also making strides in addressing MPox in the Democratic Republic of Congo. The antiviral is cleared for Phase II clinical trials after WHO declared MPox a Public Health Emergency. No approved treatment for MPox exists, with Tecovirimat failing in trials.

NanoViricides is concurrently developing treatments for multiple respiratory viral infections, aiming to combat influenza, coronaviruses, and RSV. The company also targets herpesvirus-related neurological conditions such as Alzheimer’s.